Michal Kliment, Pavol Kertys
In the literature review the authors refer to the current knowledge of aetiology, clinical course of VVC, and a wide range of available efficacious antifungal agents, application of which, however, does not prevent relapse in chronic recurrent forms. They present characteristics of the immunological profile of such patients as well as a historical overview of various attempts to influence the disturbed balance of immunity system. The authors focus on the development of oral immunotherapy and on mechanisms which explain its therapeutic effects, as well as promising conclusions of studies, which prove its effectiveness in reducing the frequency of relapses. In conclusion they summarize the possibilities of various forms of immunotherapy to supplement successfully the therapeutic complex of chronic VVC. The authors assume that the new preparation of oral vaccinotherapy which is currently coming to the Slovak market will find its stable place in this complex.